Serological Response to SARS-CoV-2 after COVID-19 Vaccination in Lung Cancer Patients: Short Review

In comparison to the general population, lung cancer patients are more likely to suffer from severe Coronavirus disease (COVID-19) and associated mortality. Considering this increased risk, and in order to prevent symptoms and severe disease, patients with lung cancer have been prioritized for COVID-19 vaccination primary and booster doses. Despite this, the pivotal clinical trials did not include these patients, which leaves open questions regarding vaccine efficacy and humoral immune response. This review outlines the findings of recent investigations into the humoral responses of lung cancer patients to COVID-19 vaccination, particularly the primary doses and first boost.

Automated summary

Compared to the general population, lung cancer patients have a higher risk of severe COVID-19 and associated mortality. Despite being prioritized for vaccination, clinical trials did not include these patients, raising concerns about vaccine efficacy and immune response. Recent investigations have focused on the humoral responses of lung cancer patients to COVID-19 vaccination.